The use of intravenous amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome.

BACKGROUND: It was reported that intravenous amiodarone might induce ventricular fibrillation for acute treatment in patients with atrial fibrillation (AF) and Wolff-Parkinson-White (WPW) syndrome. No study was done to assess its application comprehensively in this population. METHODS: This study was a retrospective analysis and undertaken by reviewing medical records and electronic databases to search for patients admitted with tachycardia resulting from WPW syndrome and AF, who have intravenously administrated amiodarone at the emergency department from January 2008 to June 2018. RESULTS: Thirty patients were involved in this study, of which 27 were males. The mean age of the patients was 47.8 ± 17.0 years. The mean systolic blood pressure and diastolic blood pressure were 111.9 ± 18.3 mmHg and 76.1 ± 14.6 mmHg, respectively. The mean heart rate was 171 (150-189) beats per minute. Half of the patients (53.3%) had no comorbidities, and only one had prior syncope. Nearly 17 patients (56.7%) started with a loading dose of 150 mg. No ventricular acceleration or VF developed. The incidence of hypotension was 3.3% (1/30). Eighteen patients (60.0%) restored to sinus rhythm by amiodarone with the conversion time of 486.0 (229.0-1278.0) minutes. CONCLUSIONS: Intravenous amiodarone might be an alternative for acute treatment of AF and WPW syndrome in patients characterized by stable hemodynamics, relatively low admission heart rate, few comorbidities, elder age, and no prior syncope. The loading dosage of 150 mg appeared to be preferred, and the maintenance period was better to less than 12 hours. Monitoring and electrolyte correction were also necessary. It is essential to keep a defibrillator nearby during pharmacologic cardioversion.

Aborted sudden cardiac death in a young soldier with concomitant hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome.

We present a young soldier presenting with aborted sudden cardiac death, who was found to have concomitant hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome. Along with pathological haemodynamic features of hypertrophic cardiomyopathy, an easily-inducible re-entrant tachycardia was clearly documented in our patient. Given the fatal potential of supraventricular tachycardia in hypertrophic cardiomyopathy, we postulated that his tachyarrhythmia could potentially trigger the event. Upon his refusal to receive implantable cardioverter/defibrillator therapy, we ablated anatomical arrhythmogenic substrate instead, and he remained uneventfully over 3 years on ß-blocker.

Clinical course and treatment of children and adolescents with the preexcitation syndrome - own studies.

INTRODUCTION: Essentially, preexcitation syndrome is the presence of an accessory pathway in the heart, which can lead to serious consequences, ranging from atrioventricular reentrant tachycardia to sudden cardiac death. Wolff-Parkinson-White syndrome is the most common preexcitation syndrome. AIM OF THE STUDY: The aim of the study was to evaluate the clinical course of the disease, as well as the treatment of children and adolescents hospitalized in the Department of Pediatric Cardiology in the years 2008-2015. MATERIALS AND METHODS: The study was carried out in 45 children (62 % male, 38% female; the mean age 11 years). During the study we analyzed 12-lead ECG, 24-hour Holter ECG, echocardiography and the cycloergometric exercise test. The results of treatment were also discussed. RESULTS: Apart from the typical features of preexcitation, the most prevalent abnormality found in ECG was atrioventricular reentrant tachycardia. In 24-hour Holter ECG the most frequently detected disorders were premature ventricular beats and premature atrial contractions. Structural heart defects were detected in 8.9% of the children. The cycloergometric exercise test was positive in 8.9% of patients. The mean duration of symptoms before the diagnosis was 2.5 years. 25% of the patients were asymptomatic. 42.2% of the children needed antiarrhythmic therapy, while 44.4% had accessory pathways ablated. CONCLUSIONS: The most common symptom of preexcitation in the study group were heart palpitations. The most frequent type of arrhythmia in children with preexcitation syndrome was orthodromic atrioventricular reentrant tachycardia. For the majority of older children ablation of the accessory pathway was a recommended form of treatment. In younger children the standard preventive pharmacological treatment was applied for 6 to 12 months.

Pharmacologic therapy with flecainide for asymptomatic Wolff-Parkinson-White syndrome in an infant with severe left ventricular dyssynchrony.

Some asymptomatic patients with Wolff-Parkinson-White syndrome have severe left ventricular dyssynchrony and dysfunction. We describe a patient who was given a diagnosis of Wolff-Parkinson-White syndrome in infancy and had a complete response to pharmacologic therapy with flecainide. Our findings suggest that flecainide is a suitable resynchronisation therapy for such infants.

The use of sugammadex in a pregnant patient with Wolff-Parkinson-White syndrome.

Wolff-Parkinson-White (WPW) syndrome is a rare pre-excitation syndrome which develops when atrioventricular conduction occurs through a pathologic accessory pathway known as the bundle of Kent instead of atrioventricular node, hence resulting in tachycardia. Patients with WPW syndrome may experience various symptoms arising from mild-to-moderate chest disease, palpitations, hypotension, and severe cardiopulmonary dysfunction. These patients are most often symptomatic because of cardiac arrhythmias. In this case report, we present an uneventful anesthetic management of a pregnant patient with WPW syndrome undergoing cesarean delivery. A 23-year-old American Society of Anesthesiologists class 2 pregnant patient was diagnosed with WPW syndrome. Her preoperative 12-lead electrocardiogram showed a sinus rhythm at 82 beats per minute, a delta wave, and a short PR interval. After an uneventful surgery, sugammadex 2mg/kg was administered as a reversal agent instead of neostigmine. Then she was discharged to her obstetrics service. Serious hemodynamic disorders may occur in patients with WPW syndrome due to development of fatal arrhythmias. Neostigmine used as a reversal agent in general anesthesia can trigger such fatal arrhythmias by leading changes in cardiac conduction. We believe that sugammadex, which is safely used in many areas in the scope of clinical practice, can be also used for patients diagnosed with WPW syndrome.

Adenosine and Preexcitation Variants: Reappraisal of Electrocardiographic Changes.

Intravenous adenosine is a short-acting blocker of the atrioventricular node that has been used to unmask subtle or latent preexcitation, and also to enable catheter ablation in selected patients with absent or intermittent preexcitation. Depending on the accessory pathway characteristics, intravenous adenosine may produce specific electrocardiographic changes highly suggestive of the preexcitation variant. Herein, we view different ECG responses to this pharmacological test in various preexcitation patterns that were confirmed by electrophysiological studies. Careful analysis of electrocardiographic changes during adenosine test, with emphasis on P-delta interval, preexcitation degree, and atrioventricular block, can be helpful to diagnose the preexcitation variant/pattern.

Nova mutação no gene PRKAG2 associado a parada cardiorrespiratória, insuficiência cardíaca congestiva e múltiplas vias acessórias / A novel mutation in the PRKAG2 gene associated with cardiorespiratory arrest, congestive heart failure and accessory pathways

Relata-se o caso de paciente do sexo masculino portador de síndrome de Wolff-Parkinson-White,hipertrofia ventricular e doença do sistema de condução, que apresentou duas paradas cardiorrespiratórias,insuficiência cardíaca congestiva e uma nova variação no gene PRKAG2.

We report the case of a male patient suffering from Wolff-Parkinson-White syndrome, ventricularhypertrophy, cardiac conduction system disease, who presented two cardiorespiratory arrests, congestive heartfailure and a new variation in the PRKAG2 gene.

Catheter ablation of drug resistant supraventricular tachycardia in neonates and infants.

BACKGROUND: The aim of this study was to evaluate the indications, results and complications of radiofrequency ablation (RFA) and transcatheter cryoablation (TCA) in neonates and infants with incessant drug-resistant supraventricular tachycardia (SVT). METHODS: Out of 225 patients who underwent RFA and TCA at our center between January2010 and February 2012, 5 patients under the age of 1 (4 male, 1 female) were evaluated. The indication for RFA/TCA was recurrent hemodynamically compromising drug-resistant SVT. RESULTS: Over a 2-year period, 6 ablation procedures were performed in 5 patients. Average patient age was 3.3 ± 3.9 months (12 days - 9.5 months); average patient weight was 5.4 ± 2.2 kg (3.5-9 kg). One patient had ventricular septal defect, 1 had corrected transposition of great arteries, ventricular septal defect, right ventricular hypoplasia and pulmonary hypertension, while 3 had only patent foramen ovale. Electrophysiology study showed 1 accessory pathway in each patient (right posteroseptal in 2, left posteroseptal in 2 and left lateral in 1). The pathway was manifest in 1 patient with Wolff-Parkinson-White syndrome (WPW) and concealed in the rest. Two of the concealed pathways had slow conduction time and decremental properties (the permanent form of junctional reciprocating tachycardia). Two patients underwentTCA and 3 - RFA, with an acute success rate of 100%. In the first week after the procedure, the patient with the complex cardiac anomaly and WPW developed recurrence and under went ablation again. Four of the procedures were carried out using an electroanatomic mapping system besides fluoroscopy. Average procedure time was 167 min (100-234); fluoroscopy time was 8.2 min (0.7-19.7). None of the patients developed major complications. After the average follow-upperiod of 6.5 months (3-18), all patients were symptom-free without medication. CONCLUSIONS: RFA and TCA can be performed successfully in neonates and infants within cessant medically refractory SVT.

A case of supraventricular tachycardia associated with Wolff-Parkinson-White syndrome and pregnancy.

A 25-year-old pregnant woman was admitted with frequent episodes of supraventricular tachycardia associated with Wolf-Parkinson-White syndrome. She was treated acutely with adenosine therapy during induction of labor and post-partum. Generally, pharmacologic treatment should be undertaken only for symptomatic arrhythmias or in hemodynamically compromised patients. Adenosine is the first choice for acute treatment of supraventricular tachycardia in pregnancy; several other options exist, but all have the potential for negative side effects for mother and fetus. Direct-current cardioversion is acceptable in all stages of pregnancy.

Atrial fibrillation with wide QRS tachycardia and undiagnosed Wolff-Parkinson-White syndrome: diagnostic and therapeutic dilemmas in a pediatric patient.

A 10-year-old girl presented to the emergency department of a regional hospital with 1 episode of generalized tonic-clonic seizures. Postictal monitoring followed by a 12-lead electrocardiogram showed fast atrial fibrillation with intermittent wide QRS regular tachycardia. Immediately following this, her rhythm changed to wide QRS irregular tachycardia without hemodynamic compromise. She was suspected to have ventricular tachycardia and was treated with intravenous amiodarone with cardioversion to sinus rhythm. Subsequent electrocardiogram in sinus rhythm showed typical features of manifest Wolff-Parkinson-White (WPW) accessory pathway. This case illustrates the diagnostic and therapeutic dilemmas in patients with atrial fibrillation, wide QRS tachycardia, and undiagnosed WPW syndrome with antidromic conduction of atrial arrhythmias through the accessory pathway. Furthermore, this case demonstrates that undiagnosed wide QRS tachycardias need to be treated with drugs acting on the accessory pathway, thus keeping in mind underlying WPW syndrome as a possibility to avoid potentially catastrophic events.

Wolff-Parkinson-White syndrome and acute pulmonary embolism: a case report.

A 48-year-old woman admitted to the emerhency departments due to sudden onset of dyspnea. The diagnosis of pulmonary embolism (PE) was made and thrombolytic therapy was started. Baseline ECG showed signs of right ventricular overload and after thrombolysis, short PR, wide QRS, and delta wave indicating Wolf-Parkinson-White (WPW) pattern were appeared. In this case report, we discuss ECG of patient with PE mimicknig WPW.

Pharmacologic cardiac resynchronization of a 1-year-old boy with severe left ventricular dysfunction.

Postero-septal accessory pathways (AP) are a rare cause of intraventricular dyssynchrony and severe LV dysfunction in children. Beside the common treatment with radiofrequency ablation of septal substrates we present the case of a successful pharmacologic resynchronization in a 13/12 years old male toddler with Wolff-Parkinson-White syndrome (WPW) and severe LV dysfunction (left ventricular biplane EF of 31 %) due to intraventricular dyssynchrony with septal to posterior wall motion delay (SPWMD) of 350 ms. Interventricular mechanical delay (IVMD) was 65 ms. Using propafenone, pharmacologic cardiac resynchronization could be achieved. Pharmacologic resynchronization should be considered as safe and effective alternative to catheter ablation in very young children.

Wolff-Parkinson-White syndrome and rheumatic mitral stenosis--an uncommon association.

The coexistence of rheumatic mitral stenosis and Wolff-Parkinson-White syndrome is an uncommon entity. We report here one such case.

Safety and efficacy of flecainide in the treatment of symptomatic children with Wolff-Parkinson-White syndrome.

Sudden cardiac death may occur in children with symptomatic and asymptomatic Wolff-Parkinson-White syndrome (WPWS). Symptomatic patients are usually treated with antiarrhythmic drugs until ablation of an accessory pathway (AP) could be performed. The objective of this study was to review the safety and efficacy of flecainide in the treatment of children with symptomatic WPWS. Twenty-two children (14 male) with WPWS and without structural heart disease were studied. AP location was achieved by electrophysiological testing or 12-lead electrocardiogram tracing. Symptomatic children (i.e., those frequent palpitations or supraventricular tachycardia episodes) received flecainide. Patients were followed-up for an average of 3.4 years until ablation of AP. Eighteen children reported clinical symptoms when first diagnosed, but only 13 initiated treatment during 16.23 months (range 1-55). Flecainide was effective in all patients: Seven became asymptomatic, and six experimented isolated episodes of palpitations. One child experienced hair loss as a side effect. AP location was as follows: left free wall (n = 7), right free wall (n = 4), posteroseptal (n = 8), and anteroseptal (n = 4). Ablation was performed without complications in 13 children. Symptomatic WPWS in children can be treated safely and efficiently with flecainide. It represents a good alternative therapy until AP ablation can be performed.

Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.

The objective of this review is to explore and challenge the superiority of amiodarone for rate control in Wolff-Parkinson-White syndrome and concomitant atrial fibrillation (WPW-AF). The current recommendation for pharmacological treatment of this condition is amiodarone. A review of the past 25 years of literature finds several studies that identify a small risk of ventricular fibrillation secondary to amiodarone administration for rate control in WPW-AF. Additionally, the literature supports the safe and effective use of procainamide for rate control in WPW-AF. This review concludes that amiodarone is not superior to procainamide in rate control for WPW-AF, and may be dangerous.

Amiodarone-induced torsade de pointes in a patient with wolff-Parkinson-White syndrome.

Amiodarone is generally regarded to have a high safety profile with a low incidence of arrhythmias. However, there have been reports of torsades de pointes under certain conditions, such as electrolyte imbalance or concomitant antiarrhythmic therapy. We describe a case of amiodarone-induced torsade de pointes early after initiation of intravenous amiodarone in the setting of T-wave alternans.